Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Nagai, Hirokazu, Fukuhara, Noriko, Kitano, Toshiyuki, Ishikawa, Takayuki, Nishikawa, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661957/
https://www.ncbi.nlm.nih.gov/pubmed/31257351
http://dx.doi.org/10.3960/jslrt.19006
_version_ 1783439558547865600
author Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Nishikawa, Tomoaki
author_facet Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Nishikawa, Tomoaki
author_sort Maruyama, Dai
collection PubMed
description
format Online
Article
Text
id pubmed-6661957
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher JSLRT
record_format MEDLINE/PubMed
spelling pubmed-66619572019-08-13 Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma Maruyama, Dai Nagai, Hirokazu Fukuhara, Noriko Kitano, Toshiyuki Ishikawa, Takayuki Nishikawa, Tomoaki J Clin Exp Hematop Letter to the Editor JSLRT 2019-06-28 /pmc/articles/PMC6661957/ /pubmed/31257351 http://dx.doi.org/10.3960/jslrt.19006 Text en © 2019 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.
spellingShingle Letter to the Editor
Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Nishikawa, Tomoaki
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title_full Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title_fullStr Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title_full_unstemmed Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title_short Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
title_sort final analysis of a phase ii study of ibrutinib in japanese patients with relapsed/refractory mantle cell lymphoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661957/
https://www.ncbi.nlm.nih.gov/pubmed/31257351
http://dx.doi.org/10.3960/jslrt.19006
work_keys_str_mv AT maruyamadai finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma
AT nagaihirokazu finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma
AT fukuharanoriko finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma
AT kitanotoshiyuki finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma
AT ishikawatakayuki finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma
AT nishikawatomoaki finalanalysisofaphaseiistudyofibrutinibinjapanesepatientswithrelapsedrefractorymantlecelllymphoma

Ejemplares similares